Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Xilio Therapeutics, Inc. XLO

Healthcare  —  Biotechnology
9.04 0.04 0.44% as of 25 Sep
Market cap
$59.2M
P/E
0.0×
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Xilio Therapeutics, Inc. (XLO) Business Profile

Updated before January 2025

Company Overview

Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biotechnology company dedicated to revolutionizing cancer treatment through the development of tumor-selective immuno-oncology therapies. Founded in 2016 and headquartered in Waltham, Massachusetts, Xilio was established with the mission of addressing the limitations of existing cancer therapies by creating treatments that maximize efficacy while minimizing systemic toxicity. The company’s name, derived from the Latin word “exilio,” meaning “to leap out,” reflects its commitment to groundbreaking innovation in oncology.

Xilio’s leadership team comprises seasoned professionals with extensive experience in biotechnology, oncology, and drug development. Key figures include René Russo, Pharm.D., BCPS, who serves as the Chief Executive Officer, and Martin Huber, M.D., the Chief Medical Officer. Together, they lead a team of scientists and executives dedicated to advancing the company’s proprietary technology platform and clinical pipeline.

Core Business Segments

Xilio Therapeutics focuses on the development of tumor-selective therapies designed to improve the therapeutic index of immuno-oncology treatments. The company’s core business segments include:

Tumor-Selective Cytokines

Xilio’s proprietary platform enables the development of cytokines that are selectively activated within the tumor microenvironment. These therapies aim to enhance anti-tumor immune responses while reducing systemic toxicity. Key products in this category include:

  • XTX202: A tumor-selective interleukin-2 (IL-2) therapy currently in clinical trials for the treatment of solid tumors.
  • XTX101: A tumor-selective anti-CTLA-4 monoclonal antibody designed to improve immune checkpoint inhibition.

Tumor-Selective Immune Checkpoint Inhibitors

Xilio is also developing immune checkpoint inhibitors that are activated specifically within tumors. These therapies aim to overcome the limitations of traditional checkpoint inhibitors by reducing off-target effects and enhancing efficacy.

Preclinical Programs

In addition to its clinical-stage assets, Xilio is advancing a robust pipeline of preclinical programs targeting various cytokines and immune checkpoint pathways. These programs are designed to expand the company’s therapeutic portfolio and address unmet needs in oncology.

Business Model

Xilio Therapeutics operates on a research-driven business model that integrates cutting-edge science with strategic partnerships to advance its clinical pipeline. The company generates revenue primarily through collaborations and licensing agreements with pharmaceutical and biotechnology companies. By leveraging its proprietary technology platform, Xilio aims to create differentiated therapies that address significant gaps in cancer treatment.

Key elements of Xilio’s business model include:

  • Proprietary Technology Platform: Xilio’s platform enables the development of tumor-selective therapies that maximize efficacy and minimize toxicity.
  • Strategic Collaborations: The company partners with leading organizations to accelerate the development and commercialization of its therapies.
  • Clinical Development: Xilio invests heavily in clinical trials to validate the safety and efficacy of its pipeline assets.

Strategic Direction

Xilio Therapeutics is committed to advancing its mission of transforming cancer treatment through innovation. The company’s strategic priorities include:

  • Pipeline Expansion: Xilio aims to broaden its therapeutic portfolio by advancing its preclinical programs and exploring new targets in immuno-oncology.
  • Clinical Progress: The company is focused on advancing its lead candidates, XTX202 and XTX101, through clinical trials and obtaining regulatory approvals.
  • Sustainability Goals: Xilio is dedicated to fostering a sustainable business model by prioritizing patient-centric innovation and ethical practices.
  • Global Reach: The company seeks to expand its presence in international markets through strategic partnerships and collaborations.

Competitive Landscape

Xilio Therapeutics operates in a highly competitive biotechnology sector, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb: A leader in immuno-oncology with a robust portfolio of checkpoint inhibitors.
  • Merck & Co.: Known for its blockbuster drug Keytruda, Merck is a major player in the oncology space.
  • Nektar Therapeutics: A biotechnology company focused on cytokine-based therapies.
  • Adaptimmune Therapeutics: Specializes in T-cell therapies for cancer treatment.

Despite the competitive landscape, Xilio differentiates itself through its tumor-selective technology platform and focus on improving the therapeutic index of immuno-oncology treatments.

Risk Factors

As a clinical-stage biotechnology company, Xilio Therapeutics faces several risks, including:

  • Regulatory Risks: The company’s therapies must undergo rigorous clinical trials and obtain regulatory approvals, which can be time-consuming and costly.
  • Market Dependence: Xilio’s success is heavily dependent on the commercial viability of its pipeline assets.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, making it vulnerable to supply chain disruptions.
  • Competitive Pressure: Intense competition in the biotechnology sector could impact Xilio’s market share and profitability.
  • Financial Risks: As a pre-revenue company, Xilio relies on external funding to support its operations and clinical development programs.

Recent Developments

Xilio Therapeutics has made significant progress in advancing its clinical pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Updates: The company announced positive interim data from its ongoing Phase 1 trials for XTX202 and XTX101, demonstrating promising safety and efficacy profiles.
  • Strategic Partnerships: Xilio entered into a collaboration agreement with a leading pharmaceutical company to co-develop and commercialize its tumor-selective therapies.
  • Corporate Milestones: The company successfully completed a public offering, raising additional capital to fund its clinical programs and operational activities.

Investment Considerations

Investors considering Xilio Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Xilio’s tumor-selective platform offers a unique approach to cancer treatment.
  • Strong Pipeline: The company has a robust pipeline of clinical and preclinical assets targeting high-value oncology indications.
  • Experienced Leadership: Xilio’s management team brings extensive expertise in biotechnology and drug development.

Risks

  • Clinical and Regulatory Uncertainty: The success of Xilio’s therapies depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Dependence: As a pre-revenue company, Xilio relies on external funding to sustain its operations.
  • Market Competition: The biotechnology sector is highly competitive, with numerous players vying for market share.

Conclusion

Xilio Therapeutics, Inc. is at the forefront of innovation in immuno-oncology, leveraging its tumor-selective technology platform to develop therapies that address significant unmet needs in cancer treatment. While the company faces challenges inherent to the biotechnology sector, its strong pipeline, experienced leadership, and commitment to innovation position it for long-term success. As Xilio advances its clinical programs and explores new opportunities in oncology, it remains a compelling player in the biotechnology landscape.